FOLH1 and prostate carcinoma: It is clinically used for neuroendocrine tumors in the somatostatin analogues [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE for peptide-mediated radioreceptor therapy and for treatment of prostate carcinomas by means of lutetium-177-PSMA therapy with PSMA derivatives such as PSMA-617 and PSMA-I&T [37,38,39,40,41,42,43].